Fibrate mRNA Vaccine Approved for Full Registration in Hong Kong, China
Read Time:27 Second
On December 20, Fosun Pharma announced that both the mRNA New Crown vaccine Fubitai BNT162b2 and Fubitai Bivalent vaccine were officially registered as Hong Kong drugs/products (biologicals) in China. Fubatai BNT162b2 is registered for basic immunization for people aged 12 years and above, and Fubatai bivalent vaccine is registered for booster vaccination for people aged 12 years and above. With this registration, people who wish to receive the vaccine can do so at medical institutions or clinics located in Hong Kong, China, with a prescription from their local doctor.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating